Brief: Lipidor Clinical Phase III Study Misses Primary Goal

Lipidor AB

28/10/2022 11:19

Oct 28 (Reuters) - Lipidor AB  LIPI.ST :
    * LIPIDOR ANNOUNCES RESULTS FROM THE COMPANY'S CLINICAL
PHASE III
STUDY OF AKP02 FOR PSORIASIS
    * PHASE III STUDY DID NOT ACHIEVE STUDY'S PRIMARY GOAL OF
ACHIEVING NON-INFERIORITY OF THERAPEUTIC EFFICACY IN TREATMENT
OF PSORIASIS COMPARED TO REFERENCE PRODUCT
    * HOWEVER, AKP02 SHOWS CLEARLY BETTER EFFICACY THAN PLACEBO
    * STUDY COMPARED AKP02 WITH A MARKET-LEADING PREPARATION FOR
TOPICAL TREATMENT OF MILD TO MODERATE PSORIASIS

Source text for Eikon:  ID:nMFN1s8RVQ 
Further company coverage:  LIPI.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))